logo-loader
viewAdmedus Ltd

Admedus divests Infusion business for $6.3 million in restructure based on ADAPT portfolio growth strategy

The sale enables Admedus to focus its growth and development strategy around its key ADAPT® product portfolio of biomaterial scaffolds used in heart valve repairs.

1559286357_shutterstock_482480275.jpg
Admedus reported $25.6 million total group revenue for 2018, an increase of $4.2 million compared to 2017

Admedus Ltd (ASX:AHZ) has sold part of its Infusion business to BTC Health Ltd (ASX:BTC) subsidiary BTC Specialty Health Pty Ltd for $6.3 million.

The two companies entered a business sale agreement in mid-May and all conditions under the sale agreement have been satisfied with no waivers granted.

The purchase price of $6.3 million includes $1.75 million of working capital, made up of inventory and debtors.

 

Included in the acquisition is the novation of an eight-year exclusive distribution agreement with Summit Medical Products for the ambIT® range of infusion pumps in Australia and New Zealand.

It also includes transfer of ten Infusion sales employees to BTC, including current Infusion business unit head Glenn Gilchrist, and the purchase of saleable inventory.

READ: Admedus divesting non-core business to focus on ADAPT product portfolio

The Infusion spin-off will allow Admedus to pursue its global growth strategy focusing on the commercial growth and development of ADAPT®.

Admedus generated $11 million in revenue from its ADAPT® products last year and has steadily reduced the selling, general and administration costs relative to revenue.

READ: Admedus to spin off immunotherapies business, shares surge

Speaking to Proactive in March, Admedus president & CEO Wayne Paterson said one of the key attributes of Admedus and ADAPT® technology was its non-calcification.

He said: “What that means simply is that it has longevity and durability, proven way beyond anything else out there.

“With the data coming in that shows younger patients are getting these, those valves therefore need to last longer.

“It’s a perfect storm for the Admedus TAVR (transcatheter aortic valve replacement) to slot straight into the middle of.”

READ: Admedus delivers results with heart-driven corporate strategy

ADAPT® is the medical technology company’s key asset, invented by leading research and development pioneer Professor Leon Neethling, Admedus’ cardiovascular science vice president.

Mostly used in valve repairs, ADAPT® biomaterial scaffolds are notably resistant to calcification, based on more than nine years of data.

The resistance bodes well for valve repairs in younger patients, with Admedus looking to grow its revenue base in the adult valve repair market.

Quick facts: Admedus Ltd

Price: 0.056 AUD

ASX:AHZ
Market: ASX
Market Cap: $33.08 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Admedus Ltd named herein, including the promotion by the Company of Admedus Ltd in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Admedus CEO in New York to update on recent key milestones

Admedus Ltd (ASX:AHZ) CEO Wayne Paterson visited the Proactive Investors New York studio to update on key milestones the company has achieved in the past few months, including receiving European approval on two of its products.

on 03/17/2019

2 min read